scholarly journals Significance of biochemical markers in diagnosis of bone remodeling disturbances among diabetic mellitus persons

2018 ◽  
Vol 35 (3) ◽  
pp. 24-31
Author(s):  
S. S. Safarova
Keyword(s):  
Bone Resorption ◽  
Bone Metabolism ◽  
Bone Tissue ◽  
Bone Remodeling ◽  
Serum Markers ◽  
Control Group ◽  
Bone Resorption Marker ◽  
Cross Sectional ◽  
Bone Metabolism Markers ◽  
Bone Mass Loss

Aim. To assess the influence of changes, observed in men and women with type 1and 2 diabetes mellitus (DM1, DM2) on the state of bone metabolism markers; to determine the directions of changes in bone remodeling serum markers among patients of both genders, suffering from this disease. Materials and methods. The cross-sectional study of patients, diagnosed DM1 (n = 98) and DM2 (n = 137) was conducted; the control group included 82 persons. In all patients, calciotropic hormones, the serum markers of bone remodeling, were studied. Results. The obtained results, regarding assessment of bone metabolism markers content in blood of DM1 and DM2 patients compared to the control, indicated the presence of pathological changes in bone remodeling processes in the form of decrease in osteogenesis marker PINP for patients with DM1 by 16 %, DM 2 – by 12 %, compared with the control group, and increase in bone resorption marker b-CTx in 32 % of patients with DM1 and 25 % with DM2; inconsistency of changes in bone remodeling processes in DM1 patients, with preferential alterations of bone resorption indices, was determined in 28 % of cases. Patients with DM2 had lower PINP and b-CTx levels that reflects the lower bone tissue metabolism, compared to DM1 patients, irrespective of age and duration of disease. Conclusions. The bone mass loss in the majority of the examined patients with diabetes is connected with suppression of osteogenesis and to a significantly lesser extent – with bone tissue resorption. Bone remodeling marker values in patients with DM2 are lower than with DM1. Such factors as glycemic profile compensation, duration of diabetes and presence of diabetic nephropathy are able to influence bone metabolism.

scholarly journals Bone Metabolism Markers in Sportswomen with Menstrual Cycle Dysfunctions

2011 ◽  
Vol 30 (2) ◽  
pp. 135-140 ◽  
Author(s):  
Nenad Ponorac ◽  
Nela Rašeta ◽  
Dragan Radovanović ◽  
Amela Matavulj ◽  
Jelena Popadić-Gaćeša
Keyword(s):  
Menstrual Cycle ◽  
Bone Resorption ◽  
Bone Formation ◽  
Bone Metabolism ◽  
Control Group ◽  
Primary Amenorrhea ◽  
Bone Resorption Marker ◽  
Mineral Density ◽  
Bone Metabolism Markers ◽  
Significant Difference

Bone Metabolism Markers in Sportswomen with Menstrual Cycle DysfunctionsIt is a well known fact that sportswomen with irregular menstrual cycle are exposed to the risk of diminished bone mineral density, and consequentially osteoporosis may appear. Monitoring of the levels of biochemical markers of bone metabolism enables understanding of the dynamic changes during the bone remodeling process. The objectives of the conducted research were to determine the prevalence of menstrual dysfunctions in a sports-women sample and a control group, and also to determine the levels of bone metabolism markers in groups of women with menstrual dysfunctions. The women (n=117) were separated into two groups, the experimental group (S) (n=84) comprised of three subgroups of sports women (34 women who play ball game sports, 27 athletes and 23 sport dancers) and the control group (C) (n=34). To establish the menstrual profile and dysfunction of the menstrual cycle, we used a very detailed questionnaire. The level of mid-fragment osteocalcin (N-MID osteocalcin) as a marker of bone formation was deter mined, as well as β-Cross Laps (β-CTx-bone resorption marker) via the electro luminescent immunochemistry method on an Elecsys 1010 automated machine. Primary amenorrhea was found in 7 (8.33%) and oligomenorrhea in 11 (13.09%) sportswomen, which was statistically a much higher incidence (p<0.05) than in the control group (0/34). Values of bone metabolism markers showed a statistically significant difference in the level of the bone resorption marker β-CrossLaps between the groups of amenorrheic and oligomenorrheic sportswomen in comparison to the eumenorrheic women, both sportswomen and those in the control group. Accelerated resorption was accompanied with accelerated bone formation. Menstrual dysfunctions were statistically more present in the sports-women group than in the control group and were accompanied with accelerated bone metabolism from the point of view of the increase of bone metabolism markers level.

The changes in bone turnover markers of female systemic lupus erythematousus patients without glucocorticoid

Lupus ◽  
2021 ◽  
Vol 30 (6) ◽  
pp. 965-971
Author(s):  
Wang Tianle ◽  
Zhang Yingying ◽  
Hong Baojian ◽  
Gu Juanfang ◽  
Wang Hongzhi ◽  
...  
Keyword(s):  
Bone Resorption ◽  
Bone Formation ◽  
Bone Turnover ◽  
Bone Metabolism ◽  
Bone Turnover Markers ◽  
Control Group ◽  
Bone Resorption Marker ◽  
Amino Terminal ◽  
Normal People ◽  
Turnover Markers

Objectives SLE is a chronic autoimmune disease, which can affect the level of bone metabolism and increase the risk of osteoporosis and fracture. The purpose of this research is to study the effect of SLE on bone turnover markers without the influence of glucocorticoids. Methods A total of 865 female subjects were recruited from Zhejiang Provincial People’s Hospital and the First Hospital of Jiaxing, including 391 SLE patients without the influence of glucocorticoids and 474 non-SLE people. We detected Bone turnover markers including amino-terminal propeptide of type 1 procollagen (P1NP), C-terminal turnover of β - I collagen (β-CTX), N-terminal midfragment of osteocalcin (NMID) and 25(OH)D, and analyzed the difference in Bone turnover markers between the SLE group and the control group, as well as the influence of age and season on bone metabolism in female SLE patients. Results In the SLE group, the average age was 43.93±13.95 years old. In the control group, the average age was 44.84±11.42 years old. There was no difference between the two groups (t = 1.03, P = 0.30). P1NP, NMID and 25(OH)D in the SLE group were significantly lower than those in the control group (Z = 8.44, p < 0.001; Z = 14.41, p < 0.001; Z = 2.19, p = 0.029), and β-CTX in the SLE group was significantly higher than that in the control group (Z = 2.61, p = 0.009). In addition, the levers of β-CTX, NMID, P1NP and 25(OH)D in older SLE female patients were statistically significantly higher than those in younger (ρ = 0.104, p = 0.041; ρ = 0.223, p < 0.001; ρ = 0.105, p = 0.038; ρ = 0.289, p < 0.001). Moreover, β-CTX reached a high value in summer and PINP reached a low value in winter. Conclusion The bone formation markers of female SLE patients without glucocorticoid were lower than those of normal people and the bone resorption marker was higher than that of normal people. The 25 (OH) D of female SLE patients without glucocorticoid was lower than that of normal people. The risk of osteoporosis and fracture may be higher in elderly women with SLE. The bone resorption level of female SLE patients is high in summer and the bone formation level is low in winter.

scholarly journals Levels of C-terminal propeptide of type I procollagen and oxyproline in patients with systemic lupus erythematosus: The relationship between the course of the disease and the structural and functional state of bone tissue

2017 ◽  
Vol 8 (2) ◽  
pp. 105-110
Author(s):  
S V. Shevchuk ◽  
L. P. Denyschych ◽  
L. I. Marynych
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Bone Resorption ◽  
Bone Metabolism ◽  
Bone Tissue ◽  
Lupus Erythematosus ◽  
Control Group ◽  
Type I ◽  
Systemic Lupus ◽  
X Ray ◽  
Type I Procollagen

The high prevalence of osteoporosis in patients with systemic lupus erythematosus (SLE) makes it necessary to study the abnormalities in bone metabolism, its relationship with reduced bone mineral density (BMD) and the impact of the disease on it. The aim of this study was to determine serum levels of C-terminal propeptide of type I procollagen (PICP) and oxyproline in patients with SLE, their comparison with the structural and functional state of the patients’ bone tissue and the course of the disease. We examined 58 female SLE patients. The mean age of the patients was 45.1 ± 1.0 years. The control group included 29 healthy individuals,corresponding in age and sex with the researched group. For every patient, data were recorded on age, body mass index (BMI), menstrual history, smoking, chronic SLE damage (SLICC/ACR DI) and disease activity score (SLEDAI), cumulative glucocorticoid dose, serum concentrations of interleukin-6 (IL-6) and C-reactive protein (CRP), bone formation marker (C-terminal propeptide of type I procollagen) and bone resorption marker (oxyproline). In all patients BMD was measured by DXA (Dual-energy X-ray absorptiometry) at two sites. To determine vertebral compression fractures, female SLE patients were examined with an x-ray of the thoracic and lumbar spine. We established that bone turnover markers showed a significant difference between the SLE patients and the control group, with lower levels of PICP and higher levels of oxyproline in the SLE patients. Alterations of bone metabolism were associated with the severity of the disease, active inflammation (high levels of CRP and IL-6), the age of the patients, and the high cumulative glucocorticoid dose but no correlation was found with disease duration, BMI and smoking. Patients with osteopenia, osteoporosis and fractures were significantly more frequently found among patients with reduced bone formation and increased bone resorption rate. Thus, our findings showed that female SLE patients have alterations of bone metabolism in the form of increasing serum oxyproline and reducing serum C-terminal propeptide of type I procollagen, the correction of which would slow the progression of adverse structural and functional changes in the bone tissue. 

scholarly journals Low calcium intake is associated with increased bone resorption in postmenopausal Japanese women: Yokogoshi Study

2009 ◽  
Vol 12 (12) ◽  
pp. 2366-2370 ◽  
Author(s):  
Kazutoshi Nakamura ◽  
Toshiko Saito ◽  
Akihiro Yoshihara ◽  
Miki Ishikawa ◽  
Yasuo Tsuchiya ◽  
...  
Keyword(s):  
Bone Resorption ◽  
Bone Turnover ◽  
Bone Metabolism ◽  
Type I Collagen ◽  
Community Setting ◽  
Serum Markers ◽  
Japanese Women ◽  
Type I ◽  
Cross Sectional ◽  
Markers Of Bone Turnover

AbstractObjectiveLow Ca intake is common among Japanese women, but its effect on bone metabolism has not been fully elucidated. The aim of the present study was to determine the relationship between Ca intake and serum markers of bone turnover in postmenopausal Japanese women.DesignA cross-sectional study.SettingA community setting.SubjectsSubjects were 595 home-dwelling postmenopausal Japanese women. Ca intake was assessed by a validated FFQ. Serum type I collagen cross-linked N-telopeptides (NTX) and osteocalcin were measured as markers of bone turnover. The relationships between demographic characteristics, lifestyles, serum Ca, vitamin D and intact serum parathyroid hormone and bone turnover were also assessed.ResultsThe average age of the subjects was 64·5 (sd 5·8) years and the mean Ca intake was 527 (sd 160) mg/d. Ca intake was significantly associated with serum NTX (P = 0·0104), but not with serum osteocalcin. Mean serum NTX concentration in the lowest quartile of Ca intake (<417 mg/d) was significantly higher than in the fourth, referent quartile. Among these Japanese postmenopausal women, very low Ca intake (less than ∼400 mg/d) was associated with increased bone resorption but not bone formation.ConclusionsIncreased bone resorption may be one mechanism by which this Ca-depleted population normalizes bone metabolism and prevents osteoporosis.

scholarly journals Effect of Vitamin E Supplement on Bone Turnover Markers in Postmenopausal Osteopenic Women: A Double-Blind, Randomized, Placebo-Controlled Trial

Nutrients ◽  
2021 ◽  
Vol 13 (12) ◽  
pp. 4226
Author(s):  
Sakda Arj-Ong Vallibhakara ◽  
Katanyuta Nakpalat ◽  
Areepan Sophonsritsuk ◽  
Chananya Tantitham ◽  
Orawin Vallibhakara
Keyword(s):  
Placebo Group ◽  
Vitamin E ◽  
Bone Resorption ◽  
Bone Turnover ◽  
Bone Remodeling ◽  
Controlled Trial ◽  
Control Group ◽  
Bone Resorption Marker ◽  
Type I ◽  
Significant Difference

Vitamin E is a strong anti-oxidative stress agent that affects the bone remodeling process. This study evaluates the effect of mixed-tocopherol supplements on bone remodeling in postmenopausal osteopenic women. A double-blinded, randomized, placebo-controlled trial study was designed to measure the effect of mixed-tocopherol on the bone turnover marker after 12 weeks of supplementation. All 52 osteopenic postmenopausal women were enrolled and allocated into two groups. The intervention group received mixed-tocopherol 400 IU/day, while the control group received placebo tablets. Fifty-two participants completed 12 weeks of follow-up. Under an intention-to-treat analysis, vitamin E produced a significant difference in the mean bone resorption marker (serum C-terminal telopeptide of type I collagen (CTX)) compared with the placebo group (−0.003 ± 0.09 and 0.121 ± 0.15, respectively (p < 0.001)). In the placebo group, the CTX had increased by 35.3% at 12 weeks of supplementation versus baseline (p < 0.001), while, in the vitamin E group, there was no significant change of bone resorption marker (p < 0.898). In conclusion, vitamin E (mixed-tocopherol) supplementation in postmenopausal osteopenic women may have a preventive effect on bone loss through anti-resorptive activity.

scholarly journals Genes associated with inflammation and bone remodeling are highly expressed in the bone of patients with the early-stage cam-type femoroacetabular impingement

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Guanying Gao ◽  
Ruiqi Wu ◽  
Rongge Liu ◽  
Jianquan Wang ◽  
Yingfang Ao ◽  
...  
Keyword(s):  
Gene Expression ◽  
Bone Tissue ◽  
Bone Remodeling ◽  
Femoroacetabular Impingement ◽  
Early Stage ◽  
Control Group ◽  
Tissue Samples ◽  
Expression Levels ◽  
Normal Bone ◽  
Impingement Zone

Abstract Background Recent studies have shown high expression levels of certain inflammatory, anabolic, and catabolic genes in the articular cartilage from the impingement zone of the hips with femoroacetabular impingement (FAI), representing an increased metabolic state. Nevertheless, little is known about the molecular properties of bone tissue from the impingement zone of hips with FAI. Methods Bone tissue samples from patients with early-stage cam-type FAI were collected during hip arthroscopy for treatment of cam-type FAI. Control bone tissue samples were collected from six patients who underwent total hip replacement because of a femoral neck fracture. Quantitative real-time polymerase chain reaction (PCR) was performed to determine the gene expression associated with inflammation and bone remodeling. The differences in the gene expression in bone tissues from the patients with early-stage cam-type FAI were also evaluated based on clinical parameters. Results In all, 12 patients with early-stage cam-type FAI and six patients in the control group were included in this study. Compared to the control samples, the bone tissue samples from patients with FAI showed higher expression levels of interleukin-6 (IL-6), alkaline phosphatase (ALP), receptor activator of nuclear factor-kB ligand (RANKL), and osteoprotegerin (OPG) (P < 0.05). IL-1 expression was detected only in the control group. On the other hand, there was no significant difference in IL-8 expression between the patients with FAI and the control group. The patients with FAI having a body mass index (BMI) of >24 kg/m2 showed higher ALP expression (P < 0.05). Further, the expression of IL-6 and ALP was higher in the patients with FAI in whom the lateral center-edge angle was >30° (P < 0.05). Conclusions Our results indicated the metabolic condition of bone tissues in patients with early-stage cam-type FAI differed from that of normal bone in the femoral head-neck junction. The expression levels of the genes associated with inflammation and bone remodeling were higher in the bone tissue of patients with early-stage cam-type FAI than in the patients with normal bone tissue.

scholarly journals DON-induced changes in bone homeostasis in mink dams

2017 ◽  
Vol 61 (3) ◽  
pp. 357-362 ◽  
Author(s):  
Ewa Tomaszewska ◽  
Piotr Dobrowolski ◽  
Siemowit Muszyński ◽  
Krzysztof Kostro ◽  
Iwona Taszkun ◽  
...  
Keyword(s):  
Bone Tissue ◽  
Bone Mineral ◽  
Wall Thickness ◽  
Vertical Wall ◽  
Control Group ◽  
Bone Homeostasis ◽  
Mineral Density ◽  
Cross Sectional ◽  
Final Body Weight ◽  
Induced Changes

AbstractIntroduction: The aim of the study was to investigate the mechanical and geometric properties as well as bone tissue and mineral density of long bones in mink dams exposed to deoxynivalenol (DON) since one day after mating, throughout gestation (ca. 46 d) and lactation to pelt harvesting. Material and Methods: Thirty clinically healthy multiparous minks (Neovison vison) of the standard dark brown type were used. After the mating, the minks were randomly assigned into two equal groups: nontreated control group and DON group fed wheat contaminated naturally with DON at a concentration of 1.1 mg·kg-1of feed. Results: The final body weight and weight and length of the femur did not differ between the groups. However, DON contamination decreased mechanical endurance of the femur. Furthermore, DON reduced the mean relative wall thickness and vertical wall thickness of the femur, while vertical cortical index, midshaft volume, and cross-sectional moment of inertia increased. Finally, DON contamination did not alter bone tissue density, bone mineral density, or bone mineral content, but decreased the values of all investigated structural and material properties. Conclusion: DON at applied concentration probably intensified the process of endosteal resorption, which was the main reason for bone wall thinning and the weakening of the whole bone.

P1402USE OF ROMOSOZUMAB FOR OSTEOPOROSIS IN HEMODIALYSIS PATIENTS

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Rie Kiyosumi ◽  
Naofumi Ikeda
Keyword(s):  
Bone Density ◽  
Bone Metabolism ◽  
Hemodialysis Patients ◽  
Bone Resorption Marker ◽  
Dialysis Patients ◽  
Bone Metabolism Markers ◽  
Mean Values ◽  
Metabolic Marker ◽  
Tracp 5B ◽  
Whole Pth

Abstract Background and Aims Recently, the importance of osteoporosis and chronic kidney disease-mineral bone disorder (CKD-MBD) has been highlighted as a cause of increased fracture risk in dialysis patients. However, many osteoporosis drugs require careful administration or are contraindicated in dialysis patients, and evidence for their use in dialysis patients is scarce. Here, we administered the new human anti-sclerostin antibody preparation romosozumab to hemodialysis patients with osteoporosis, and examined changes in bone density, bone metabolism markers and other values. Method Romosozumab was administered once per month to 12 hemodialysis patients (mean age: 72.6 ± 9.4 years old; 4 males, 8 females) who were diagnosed with osteoporosis while visiting our hospital and who had no history of cardiovascular complications in the preceding year. Bone density YAM value was measured every 3 months by dual energy X-ray absorptiometry (DXA). TRACP-5b, BAP, P1NP and whole-PTH values were measured every month as bone metabolic markers. Values at the start of observation were regarded as pre-dosing values and the mean values during the 6 months after administration were measured as post-treatment values. The results were then compared. Results At 6 months after the start of treatment, no change was seen in bone density of the proximal femur compared to the pre-dosing value. In contrast, lumbar spine bone density YAM value (%) was significantly improved, from 63.8% ± 9.4% to 70.9% ± 5.2% (P = 0.012). Regarding bone metabolism markers, mean value of bone resorption marker TRACP-5b after the start of administration did not significantly differ from that at the start of observation. BAP value increased significantly from 16.2 ± 8.7 to 25.2 ± 11.0 (p &lt; 0.01) while whole-PTH significantly increased from 103.5 ± 52.8 to 236.1 ± 100.8 (p &lt; 0.01). In addition, serial time changes for each bone metabolic marker, whole-PTH value, and corrected Ca value during the observation period are also reported. Conclusion Romosozumab may improve bone density in dialysis patients with osteoporosis.

scholarly journals Feeding and Bone Turnover in Gastric Bypass

2014 ◽  
Vol 99 (2) ◽  
pp. 491-497 ◽  
Author(s):  
Juan P. Valderas ◽  
Oslando Padilla ◽  
Sandra Solari ◽  
Manuel Escalona ◽  
Gilberto González
Keyword(s):  
Gastric Bypass ◽  
Bone Resorption ◽  
Bone Turnover ◽  
Area Under The Curve ◽  
Significant Negative Correlation ◽  
University Hospital ◽  
Control Group ◽  
Type I ◽  
Cross Sectional ◽  
Calcium Phosphorus

Context: Roux-en-Y gastric bypass (RYGB) is associated with high bone turnover. In healthy subjects, feeding causes acute reduction of bone resorption, which is regulated by several intestinal and pancreatic peptides. Objective: Our objective was to assess bone turnover after feeding in patients with RYGB. Design and Setting: This was a cross-sectional case-control study at a university hospital. Participants: Fifteen postmenopausal women who underwent RYGB 7.4 ± 4.1 years previously were matched by age and body mass index with 15 nonoperated women (controls). Main Outcomes: Serum PTH, calcium, phosphorus, insulin, carboxy telopeptide (CTX), procollagen type I N-terminal propeptide (P1NP), and glucagon-like peptide 2 (GLP-2) were measured while fasting and after a standard meal (SM). Results: The fasting calcium, phosphorus, and PTH were similar in both groups and exhibited similar decreases after an SM. The fasting CTX level was higher in the RYGB than in the control group (0.589 ± 0.18 vs 0.382 ± 0.11 ng/mL; P &lt; .05) and fell to a nadir of 42.2% of the basal value in the RYGB and 53.9% in controls (P &lt; .05). The fasting and postprandial P1NP levels were similar in both groups and fell to a nadir of 85.8% in the RYGB and 89.3% in controls. Insulin and GLP-2 levels were similar during fasting in both groups. RYGB patients had exaggerated postprandial insulin and GLP-2 response compared with the controls with the insulin and GLP-2 area under the curve being significantly higher in the RYGB group. There was a significant negative correlation between the peak of insulin levels and the CTX changes. Conclusion: The acute reduction in bone resorption after feeding is preserved in RYGB and is even higher than in nonoperated subjects. This phenomenon is related to the increase of postprandial levels of insulin. These findings suggest a bone-protecting mechanism in RYGB that may counteract the elevated bone resorption that occurs during fasting.

scholarly journals Lipoprotein-Associated Phospholipase A2 Is Increased in Patients with Impaired Bone Density

2014 ◽  
Vol 33 (4) ◽  
pp. 317-322
Author(s):  
Karel Kotaška ◽  
Jitka Kolárová ◽  
Blanka Jedličková ◽  
Jana Čepová ◽  
Jan Kotaška ◽  
...  
Keyword(s):  
Bone Density ◽  
Bone Resorption ◽  
Bone Metabolism ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Serum Levels ◽  
Phospholipase A ◽  
Control Group ◽  
Low Density ◽  
Healthy Individuals

Summary Background: Increased levels of lipoprotein-associated phospholipase A2 are associated with atherosclerosis, and may contribute to cardiac disease. The aim of this study was to analyze serum levels of lipoprotein phospholipase A2 (Lp-PLA2) in patients with impaired bone resorption and correlate the findings with markers of bone metabolism (osteocalcin) and other biochemical markers (cholesterol, low density lipoprotein, triacylglycerols). Methods: Serum Lp-PLA2 was measured by a turbidimetric method in a group of currently treated 85 patients with impaired bone resorption and in a control group of 46 healthy individuals. Serum triacylglycerols was measured by the electrochemiluminescence immunoassay. Cholesterol, low density lipoprotein and triacylglycerols were measured by commercially available enzymatic assays. Bone density was investigated by dual energy X-ray densitometry performed on the lower spine and hips. Results: Concentrations of LP-PLA2 were significantly elevated in the patients with bone resorption compared to the control group of healthy individuals (225 ng/mL vs. 192 ng/mL, p>0.001) with the highest difference in patients with a T score below –2.5 SD (227 vs. 192 ng/mL). Serum levels of Lp-PLA2 also negatively correlated with decreased levels of serum osteocalcin in patients, and a significant difference in Lp-PLA2 (p=0.02) levels was observed between the control group and group with low levels of osteocalcin. Elevated Lp-PLA2 levels were significantly associated with the therapeutic procedures used, but not with age, gender and concentration of lipids. Conclusions: Lipoprotein-associated phospholipase A2 seems to play an important role also in bone metabolism.

Sign in / Sign up

Export Citation Format

Share Document